Table 3

Associations between HLA-DRB1 alleles and vascular events among patients with systemic lupus erythematosus (SLE)

Meta-analyses
N (%)OR (95% CI)p Value
DRB1*01
AVE24 (11.4)0.83 (0.51 to 1.38)0.48
AAE16 (11.4)0.84 (0.47 to 1.50)0.55
ICVD8 (10.3)0.74 (0.34 to 1.60)0.45
Stroke7 (10.4)0.81 (0.37 to 1.79)0.60
IHD7 (10.1)0.65 (0.29 to 1.48)0.30
MI5 (9.1)0.63 (0.25 to 1.57)0.32
IPVD4 (12.5)0.96 (0.34 to 2.68)0.94
VTE12 (11.2)0.83 (0.43 to 1.60)0.59
DRB1*03
AVE93 (44.1)0.82 (0.59 to 1.15)0.25
AAE65 (46.1)0.94 (0.64 to 1.36)0.73
ICVD34 (43.6)0.85 (0.53 to 1.37)0.50
Stroke28 (41.8)0.78 (0.47 to 1.30)0.34
IHD33 (47.8)0.96 (0.58 to 1.58)0.87
MI27 (49.1)1.01 (0.58 to 1.76)0.96
IPVD17 (53.1)1.20 (0.59 to 2.46)0.62
VTE48 (44.9)0.88 (0.58 to 1.34)0.55
DRB1*04
AVE68 (32.2)1.18 (0.83 to 1.68)0.36
AAE48 (34.0)1.28 (0.86 to 1.90)0.22
ICVD33 (42.3)1.88 (1.16 to 3.05)0.01
Stroke27 (40.3)1.70 (1.01 to 2.86)0.05
IHD25 (36.2)1.37 (0.81 to 2.32)0.23
MI22 (40,0)1.62 (0.92 to 2.87)0.09
IPVD12 (37.5)1.42 (0.68 to 2.96)0.35
VTE34 (31.8)1.12 (0.72 to 1.74)0.63
DRB1*13
AVE67 (31.8)1.67 (1.15 to 2.41)0.006
AAE42 (29.8)1.36 (0.90 to 2.07)0.14
ICVD25 (32.1)1.49 (0.89 to 2.48)0.13
Stroke22 (32.8)1.54 (0.90 to 2.65)0.12
IHD19 (27.5)1.20 (0.68 to 2.11)0.53
MI15 (27.3)1.12 (0.60 to 2.09)0.71
IPVD7 (21.9)0.86 (0.37 to 1.99)0.73
VTE34 (20.5)1.50 (0.95 to 2.35)0.08
DRB1*15
AVE66 (31.3)0.74 (0.52 to 1.04)0.09
AAE46 (32.6)0.83 (0.56 to 1.23)0.36
ICVD27 (34.6)0.93 (0.56 to 1.54)0.76
Stroke24 (35.8)0.98 (0.58 to 1.66)0.94
IHD24 (34.8)0.95 (0.56 to 1.60)0.85
MI21 (38.2)1.12 (0.63 to 1.98)0.70
IPVD5 (15.6)0.32 (0.12 to 0.84)0.02
VTE35 (32.7)0.84 (0.54 to 1.31)0.45
  • N represents number of cases positive for the particular DRB1 allele and positive for the vascular phenotype; (%) represents percentage of the total number positive for the phenotype (eg, how many patients out of all who have had stroke are DRB1*01 positive).

  • AAE, any arterial event; AVE, any vascular event; ICVD, ischaemic cerebrovascular disease; IHD, ischaemic heart disease; IPVD, ischaemic peripheral vascular disease; MI, myocardial infarction; VTE, venous thromboembolism.